Deutsche Effecten- und Wechsel-Beteiligungsges. AG
EANS-News: DEWB Investment Holding NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12
Berlin, Germany, September 3, 2009 (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information/Investment holdings
NOXXON Pharma AG
(NOXXON), clinical-stage developer of L-RNA based scaffolds
(Spiegelmers®) that bind their targets conceptually similar to
antibodies, announced today that the company was awarded a research
grant from Germany´s Federal Ministry of Education and Research
(BMBF) under the ministry´s small and medium enterprise innovation
initiative ("KMU-Innovativ"). The grant was presented to NOXXON
following the completion of a peer reviewed selection process. Under
the initiative NOXXON will receive 1.2 million Euro (1.7 million US$)
in funding for the impending phase I clinical development of its
candidate Spiegelmer® NOX-A12. The company develops NOX-A12 for use
in autologous hematopoietic stem cell transplantation in patients
suffering from non-Hodgkin´s lymphoma or multiple myeloma.NOXXON´s Chief Executive Officer Frank Morich commented: "In awarding this competitive research grant to NOXXON, the BMBF acknowledges our tremendous progress in maturing Spiegelmer® compounds into therapeutic candidates for human use. The transition from pre-clinical studies to clinical trials is a critical junction in the development of an innovative compound. We are grateful to the BMBF for providing grant support at this crucial stage."
Spiegelmers® (L-aptamers) are chemical entities based on synthetic mirror-image oligonucleotides. Due to their unique mirror image configuration Spiegelmers® are not metabolized and do not hybridize with native nucleic acids. Spiegelmers® also do not activate the innate immune response via Toll-like receptors and have shown an exceptionally favorable immunogenicity profile in pre-clinical testing. The phase I clinical development of NOX-A12 will follow closely behind that of NOXXON´s lead candidate NOX-E36, which entered human testing in June of 2009.
About NOXXON Pharma AG: Berlin-based NOXXON Pharma AG is a clinical-stage biotechnology company focusing on the development of Spiegelmers® for the treatment of inflammatory diseases and hematological indications. In addition to its in-house programs NOXXON discovers and develops Spiegelmers® in collaboration with partners from the pharmaceutical industry, including Eli Lilly, Hoffmann La-Roche and Pfizer. Spiegelmers® (the German word "Spiegel" means mirror) are chemical entities based on synthetic L-nucleic acid scaffolds that bind their targets conceptually similar to monoclonal antibodies. They are highly selective for their pharmacological target and potent inhibitors of target function. The substance class exhibits exceptional metabolic stability and an outstanding immunogenicity profile - a new generation of improved therapeutics. NOXXON is an investment holding of the listed venture capital company Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB), headquartered in Jena.
Website: http://www.noxxon.com
General contact: Emmanuelle Delabre NOXXON Pharma AG Max-Dohrn-Strasse 8-10 10589 Berlin, Germany Phone: + 49-30-726247-100 FAX: + 49-30-726247-225
Email: edelabre@noxxon.com
end of announcement euro adhoc
Further inquiry note:
Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com
Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade